Literature DB >> 21500143

Hip lateralisation in children with bilateral spastic cerebral palsy treated with botulinum toxin type A: a 2-year follow-up.

N H Jung1, F Heinen, B Westhoff, L Doederlein, A Reissig, S Berweck, M Linder-Lucht, S Schandelmaier, V Mall.   

Abstract

We investigated the effect of BoNT/A injection on hip lateralisation in children with bilateral spastic cerebral palsy and bilateral adductor spasticity. Pelvic radiographs using Reimers' migration index (MI) were evaluated from 27 children (n=9 females, n=18 males; mean age 5.2 ± 1.96 years; range: 2-10 years; initial MI <50%) with bilateral spastic cerebral palsy over a time period of 2 years. All received injections of BoNT/A (Dysport) every 12 weeks with a dose of 30 Units per kilogram body weight into adductor and medial hamstring muscles on both sides. The MI was calculated before treatment and after 1 and 2 years. The mean MI increased from 25.5% (range: 0-48) to 26.7% (+1.2%, range: 0-79) on the right side and from 28.0% (range: 0-40) to 30.6% (+2.6%, range: 3-84) on the left side over 2 years, respectively. Hips of one patient dislocated bilaterally. The mean MI remained stable over 2 years. Although a specific BoNT/A effect cannot be proven because of the open design of this study, we provide strong evidence that the MI can be kept stable for a time period of 2 years under non-surgical management including therapy with BoNT/A even in CP patients with a high risk for hip dislocation. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21500143     DOI: 10.1055/s-0031-1275344

Source DB:  PubMed          Journal:  Neuropediatrics        ISSN: 0174-304X            Impact factor:   1.947


  8 in total

1.  [Long-term results of reconstructive surgery in infantile cerebral palsy patients with high hip dislocation: is hip screening necessary?].

Authors:  F Braatz; A Eidemüller; M C Klotz; S I Wolf; T Dreher
Journal:  Orthopade       Date:  2014-09       Impact factor: 1.087

2.  Hip reconstruction surgery is successful in restoring joint congruity in patients with cerebral palsy: long-term outcome.

Authors:  Frank Braatz; Annette Eidemüller; Matthias C Klotz; Nicholas A Beckmann; Sebastian I Wolf; Thomas Dreher
Journal:  Int Orthop       Date:  2014-06-27       Impact factor: 3.075

3.  Hip-joint congruity after Dega osteotomy in patients with cerebral palsy: long-term results.

Authors:  Frank Braatz; Daniel Staude; Matthias C Klotz; Sebastian I Wolf; Thomas Dreher; Stefan Lakemeier
Journal:  Int Orthop       Date:  2015-10-10       Impact factor: 3.075

4.  Migration percentage and odds of recurrence/subsequent surgery after treatment for hip subluxation in pediatric cerebral palsy: a meta-analysis and systematic review.

Authors:  K N Agarwal; C Chen; D M Scher; E R Dodwell
Journal:  J Child Orthop       Date:  2019-12-01       Impact factor: 1.548

5.  The effect of obturator nerve block on hip lateralization in low functioning children with spastic cerebral palsy.

Authors:  Eun Sook Park; Dong-Wook Rha; Won Chul Lee; Eun Geol Sim
Journal:  Yonsei Med J       Date:  2014-01       Impact factor: 2.759

6.  Long-term effect of botulinum toxin A on the hip and spine in cerebral palsy: A national retrospective cohort study in Taiwan.

Authors:  Ching-Yueh Lin; Chi-Hsiang Chung; Dennis J Matthews; Heng-Yi Chu; Liang-Cheng Chen; Sung-Sen Yang; Wu-Chien Chien
Journal:  PLoS One       Date:  2021-07-22       Impact factor: 3.240

7.  Effect of Botulinum Toxin Injection on the Progression of Hip Dislocation in Patients with Spastic Cerebral Palsy: A Pilot Study.

Authors:  Yookyung Lee; Seungeun Lee; Joonyoung Jang; Jiwoon Lim; Ju Seok Ryu
Journal:  Toxins (Basel)       Date:  2021-12-06       Impact factor: 4.546

8.  European expert consensus on improving patient selection for the management of disabling spasticity with intrathecal baclofen and/or botulinum toxin type A.

Authors:  Bo Biering-Soerensen; Valerie Stevenson; Djamel Bensmail; Klemen Grabljevec; Mercedes Martínez Moreno; Elke Pucks-Faes; Joerg Wissel; Mauro Zampolini
Journal:  J Rehabil Med       Date:  2022-01-03       Impact factor: 2.912

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.